Synergy Pharmaceuticals
11.02.2013 11:00
---------------------------------------------------------------------------
NEW YORK, 2013-02-11 11:00 CET (GLOBE NEWSWIRE) --
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat
gastrointestinal disorders and diseases, today announced that its common stock
has been approved for listing on The NASDAQ Global Market under the symbol
'SGYP.' Trading on The NASDAQ Global Market is expected to commence on February
12, 2013. The Company's units and warrants will continue to trade on The NASDAQ
Capital Market under the symbols 'SGYPU' and 'SGYPW,' respectively.
About Synergy Pharmaceuticals Inc.
Synergy is a biopharmaceutical company focused on the development of new drugs
to treat gastrointestinal disorders and diseases. Synergy's lead proprietary
drug candidate, plecanatide, is a synthetic analog of the human
gastrointestinal hormone uroguanylin, and functions by activating the guanylate
cyclase C receptor on epithelial cells of the GI tract. Synergy completed a
positive Phase I study of plecanatide in healthy volunteers, and positive Phase
IIa and Phase IIb/III clinical trials in patients with chronic idiopathic
constipation (CIC). Detailed positive findings from a recently completed Phase
IIb/III clinical trial will be presented at a major scientific meeting this
year. Synergy is also developing plecanatide for the treatment of irritable
bowel syndrome with constipation (IBS-C), having initiated the first trial in
IBS-C patients in late 2012. Synergy's second GC-C agonist, SP-333, is in
clinical development to treat inflammatory bowel diseases, and has just
completed its first Phase I trial in healthy volunteers. More information is
available at http://www.synergypharma.com.
Media Contact:
Janet Skidmore
Office: 215-658-4915
Mobile: 215-429-2917
skidmorecomm@earthlink.net
Investor Contact:
Danielle Spangler
The Trout Group
synergy@troutgroup.com
(646) 378-2924
News Source: NASDAQ OMX
11.02.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Synergy Pharmaceuticals
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US8716393082
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: Synergy Pharmaceuticals to Begin Trading on The NASDAQ Global Market
| Source: EQS Group AG